- Home
- MTZ vs ROIV Comparison
MTZ vs ROIV Comparison
Compare MTZ & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTZ | ROIV |
|---|---|---|
| Founded | 1929 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9B | 21.0B |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTZ | ROIV |
|---|---|---|
| Price | $380.43 | $31.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $339.47 | $28.94 |
| AVG Volume (30 Days) | 897.9K | ★ 5.1M |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.12 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $14,299,171,000.00 | $8,260,000.00 |
| Revenue This Year | $20.38 | N/A |
| Revenue Next Year | $10.18 | $744.61 |
| P/E Ratio | $492.69 | ★ N/A |
| Revenue Growth | ★ 16.22 | N/A |
| 52 Week Low | $160.08 | $10.71 |
| 52 Week High | $441.43 | $32.79 |
Technical Indicators
Market Signals| Indicator | MTZ | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 62.63 |
| Support Level | $369.04 | $27.44 |
| Resistance Level | $438.66 | $32.79 |
| Average True Range (ATR) | 16.05 | 0.93 |
| MACD | 1.44 | 0.22 |
| Stochastic Oscillator | 84.77 | 83.75 |
Price Performance
Historical ComparisonAbout MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; pipeline infrastructure; power delivery; and other.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.